Related content

Reporting and Interpretation of the CYP2C19 Genotyping Test for Clopidogrel Dosing

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 8, Iss. 4, 2010-12 ,pp. : 268-272

Bentham Science Publishers

Access to resources Recommend Favorite

Cost–effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia

By Sorich Michael J   Horowitz John D   Sorich Wassana   Wiese Michael D   Pekarsky Brita   Karnon Jonathan D  

Pharmacogenomics, Vol. 14, Iss. 16, 2013-12 ,pp. : 2013-2021

Future Medicine

Access to resources Recommend Favorite

Interaction Between Clopidogrel and Proton Pump Inhibitors: Hypothesis to Explain Multifactorial CYP2C19 Inhibition

By  

Drug Metabolism Letters, Vol. 3, Iss. 4, 2009-12 ,pp. : 287-289

Bentham Science Publishers

Access to resources Recommend Favorite

Research Highlights: CYP2C19 genetic variants and clopidogrel responsiveness in acute coronary syndrome: are we ready for individualized therapy?

By Giusti Betti   Gori Anna Maria   Marcucci Rossella   Abbate Rosanna  

Pharmacogenomics, Vol. 10, Iss. 7, 2009-07 ,pp. : 1131-1133

Future Medicine

Access to resources Recommend Favorite

CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor

By Furuta Takahisa   Sugimoto Mitsushige   Shirai Naohito   Ishizaki Takashi  

Pharmacogenomics, Vol. 8, Iss. 9, 2007-09 ,pp. : 1199-1210

Future Medicine

Access to resources Recommend Favorite